Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and others in the Cambridge-London life sciences corridor, and wider local and international ecosystems.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

DLRC Launches Regulatory Spark to Give Early-Stage Innovators an Investor-Ready Route to Clinic

New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.

DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.

World’s leading chocolate manufacturer Barry Callebaut moves into Gastronomica food tech incubator

Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.

Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions.

Pioneering Prevention for a Healthier Future

📣 Join HBA Cambridge and Deloitte for 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐚 𝐇𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫 𝐅𝐮𝐭𝐮𝐫𝐞 on 30 September.

This event will explore how a prevention-first approach can improve health outcomes, reduce health inequalities, strengthen healthcare sustainability, and keep the patient voice at the heart of innovation.

Hear from leaders across healthcare, life sciences, public health, and patient advocacy, with the discussion moderated by Elizabeth Hampson, UK Life Sciences and Health Innovation Partner at Deloitte.

Rare Insights: Beacon’s brand-new patient group study

Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face.

Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart.

Boyds reports strong growth despite biotech sector headwinds

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.

Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.

Project Scientist

The post holder is expected to provide expertise and support in:

  • Establishing and characterising (e.g., genotyping) mouse lines
  • Perform in vivo studies
  • Harvest tissue for analysis
  • Perform basic wet-lab techniques
  • Contribute to data collection
  • Training and supervision of staff and students in above work.

The candidate will also have access to training opportunities within the Norwich Research Park and the collaborative network to develop their laboratory and analytical skills.

Coulter Partners strengthens global leadership team with three Client Partner appointments across Spain, the US, and the UK

LONDON, UK; MADRID, Spain; and SHORT HILLS, NJ – September 16, 2026 – Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.

Subscribe to